When CSL was first established in 1916 it was to help our nation, isolated by war, to secure our medical supply chains and sovereign capability. Now over 100 years later and a global leader in biotech, CSL is manufacturing 50 million doses of the AstraZeneca COVID-19 vaccine right here on our shores.
They will begin being rolled out from the end of March, joining Pfizer’s vaccine, which is already being administered, as part of our program to keep Australians safe and protect our way of life.
Pfizer’s successful mRNA vaccine has sparked a lot of discussion about Australia’s capability to produce these cutting-edge types of treatments.
The reality is producing mRNA vaccines at scale is a brand new challenge the entire world is grappling with. But, just as we did during the height of the pandemic with manufacturing surgical masks and ventilators, we’re not taking “that’s impossible” for an answer.
We have been exploring practical options to mobilise the capability of local businesses and researchers to future proof our nation when it comes to vaccines.
Because just as CSL was born out of necessity, the COVID-19 pandemic has changed the way we all view sovereign capability and needs.